Enhanced CMC infrastructure at Cranbury site aims to improve bioavailability, streamline formulation development and support faster progression of challenging drug candidates into clinical trials
First-in-class topical androgen receptor inhibitor marks Glenmark’s first New Chemical Entity (NCE) launch in Europe
Partnership discussions focus on clinical validation, real-world evidence generation and adoption of indigenous diagnostic technologies across healthcare settings
The validation confirms the submission is complete, clearing the way for the EMA’s centralized review process to formally evaluate the therapy
The campaign aims to raise awareness of a condition that affects an estimated 24 million adults in the US, many of whom remain undiagnosed
The Prayagraj lab is designed to handle both routine and specialised testing
The award places the company in the top 5% globally
Deal brings late-stage lung cancer candidates zidesamtinib and neladalkib into GSK’s portfolio
The company gets access to Lonza’s clinically validated SYNtecan linker-payload platform as it prepares an IND filing for its acute myeloid leukemia therapy in 2027
The acquisition of Milan-based company will strengthen subsidiary Alivira Animal Health’s presence in Europe
Consolidated entity plans to strengthen specialty pharmaceutical offerings, expand manufacturing capacity, and accelerate global market penetration across emerging regions
The company says the goal is to improve consistency and efficiency in total hip arthroplasty (THA) as demand for the procedure continues to surge
Strategic shift from Italy to India strengthens supply chain resilience, expands capacity and enhances sustainability for the growing global UDCA market
Deal expands SPI Pharma’s manufacturing footprint in Germany, enhances pharmaceutical ingredient offerings, and reinforces focus on fast-growing digestive health market
Collaboration combines Lupin’s inhaler manufacturing capabilities with ERN’s strong commercial presence to expand access to respiratory care
Tomoyuki Hasegawa has been appointed CEO of FUJIFILM Biotechnologies California
The company said Wegovy hit its first one million prescriptions within 12 weeks of availability
The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format
Based on the cumulative data from ACHIEVE-1 through ACHIEVE-5, Lilly plans to submit orforglipron for FDA approval for the treatment of type 2 diabetes by the end of the second quarter
The launch comes against the backdrop of a significant public health burden
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
